KayoThera develops first-in-class oral small molecule inhibitors of the retinoid nuclear receptor pathway for oncology and cardiometabolic diseases.
Get notified the moment KayoThera, Inc. files a new round, hires execs, or shows traction signals.
Create free accountAbout this data
FlareSight surfaces funding data from SEC Form D filings within hours of submission. Browse our full startup funding database to find more recently funded companies.